Cervomed Inc CRVO

$3.28 +0.10 (3.14%)

Valuation

Market cap
48,078,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
341,600
Avg volume
274,474
Day's range
$3.13 – $3.31
Shares out
15,119,000
Stochastic %K
82%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

SRT47 Oct 8, 10:50 PM
$CRVO will announce partner for Phase 3 trial soon🤙
1 replies
Houseofsweeps Oct 8, 5:48 PM
$CRVO it’s trying here 🤞
2 replies
steven1x Oct 8, 2:52 PM
$CRVO when are they expected to announce a partner for phase3?
1 replies
Pineapple567 Oct 8, 2:28 PM
$CRVO even with the shorts in room with us, its nice to see how the stock easily has theese bounce backs
1 replies
Marcos125 Oct 8, 2:01 PM
$CRVO Let us know if there is any new news😶
1 replies
DrNeega Oct 8, 1:51 PM
$CRVO good resilience
0 replies
Mfv Oct 8, 12:45 PM
$CRVO Time for news Alam!
0 replies
generaltom Oct 8, 11:56 AM
$CRVO On Sunday, 11 October 2026, CervoMed will present initial Phase 2a clinical trial results for neflamapimod in nfvPPA, a form of frontotemporal dementia.
0 replies